Ipilimumab-associated Sweet syndrome in a melanoma patient

Gormley, Rachel H.; Wanat, Karolyn A.; Elenitsas, Rosalie; Giles, J H; McGettigan, Suzanne; Schuchter, Lynn M.; Takeshita, Junko

doi:10.1016/j.jaad.2014.06.042

Cited by 38 publications

(22 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Other less common skin reactions include Stevens-Johnson syndrome, prurigo, acneiform rash, lichenoid exanthema, pyoderma gangrenosum-like ulceration, skin toxicity in areas after radiation, photosensitivity reaction, a drug rash with eosinophilia and systemic symptoms (DRESS) (22) and Sweet syndrome (41, 42). A single case of ipilimumab-induced dermatomyositis has also been reported (43).…”

Section: Iraes In Various Organ Systemsmentioning

confidence: 99%

Immune-mediated adverse events of anticytotoxic T lymphocyte–associated antigen 4 antibody therapy in metastatic melanoma

Quirk

Shure

Agrawal

2015

Translational Research

View full text Add to dashboard Cite

Ipilimumab, an antibody that blocks cytotoxic T lymphocyte-associated antigen-4 (CTLA-4; CD152), was approved by the Food and Drug Administration (FDA) in 2011 for the treatment of unresectable stage III or IV malignant melanoma. Although the addition of this particular immunotherapy has broadened treatment options, immune-related adverse events (irAEs) are associated with ipilimumab therapy, including dermatologic effects, colitis and diarrhea, endocrine effects, hepatotoxicity, ocular effects, renal effects, neurologic effects, and others. In this article, a critical evaluation of the underlying mechanisms of irAEs associated with anti-CTLA-4 therapy is presented. Additionally, potentially beneficial effects of combinational therapies to alleviate ipilimumab-induced irAEs in malignant melanoma are discussed. Future research is warranted to elucidate the efficacy of such combination therapies as well as specific biomarkers that would help to predict a clinical response to ipilimumab in patients with malignant melanoma.

show abstract

Section: Iraes In Various Organ Systemsmentioning

confidence: 99%

Immune-mediated adverse events of anticytotoxic T lymphocyte–associated antigen 4 antibody therapy in metastatic melanoma

Quirk

Shure

Agrawal

2015

Translational Research

View full text Add to dashboard Cite

show abstract

“…In a secondary analysis of the Phase III study of ipilimumab and dacrabazine in advanced melanoma, Baurrain and coworkers found that in the majority of patients treated with ipilimumab at 10 mg/kg plus dacarbazine who received corticosteroids for the management of immune-related adverse events (including dermatitis), these adverse events had completely resolved or improved to grade 1 [40]. Rare occurrences of Sweet's syndrome, as well as StevensJohnson syndrome have been reported with ipilimumab [41]. Immune checkpoint inhibitors should be permanently discontinued in patients with grade 4 skin toxicity, and systemic steroids should be immediately initiated in these cases [42].…”

Section: Hodi Et Al (2010) Grade 3 Rash Was Noticed In 5 Patientsmentioning

confidence: 99%

Risk of Cutaneous Toxicities in Patients with Solid Tumors Treated with Immune Checkpoint Inhibitors: A Meta-Analysis

2015

View full text Add to dashboard Cite

show abstract

“…As new drugs are used, isolated case reports of drug‐induced Sweet syndrome continuously appear in the literature. Dermatologists should know that cases of Sweet syndrome have been attributed to isotretinoin, adalimumab, vemurafenib and ipilimumab, as well as bortezomib, azathioprine and antibiotics, among other drugs.…”

Section: Sweet Syndromementioning

confidence: 99%

Pyoderma gangrenosum and Sweet syndrome: the prototypic neutrophilic dermatoses

Wallach¹,

Vignon‐Pennamen

2015

Br J Dermatol

View full text Add to dashboard Cite

Pyoderma gangrenosum, a dramatic ulcerative skin disease, and Sweet syndrome, a papular dermatosis, were described independently. It was subsequently shown that they share many characteristics, including clinical overlap and the frequent association with multisystemic disorders. The group of the neutrophilic dermatoses encompasses these two dermatoses, as well as other conditions having in common an aseptic neutrophilic infiltrate predominating in the epidermis and/or the dermis and/or the subcutis. Some patients also experience neutrophilic infiltrates in other organs, defining the neutrophilic disease. Recent research suggests that the neutrophilic dermatoses could be considered as the cutaneous expression of the autoinflammation, an aberrant hyperproduction of interleukin-1. Autoinflammation is responsible for monogenic diseases, and is also involved in the mechanism of many polygenic conditions, including the neutrophilic dermatoses.

show abstract

Ipilimumab-associated Sweet syndrome in a melanoma patient

Cited by 38 publications

References 4 publications

Immune-mediated adverse events of anticytotoxic T lymphocyte–associated antigen 4 antibody therapy in metastatic melanoma

Immune-mediated adverse events of anticytotoxic T lymphocyte–associated antigen 4 antibody therapy in metastatic melanoma

Risk of Cutaneous Toxicities in Patients with Solid Tumors Treated with Immune Checkpoint Inhibitors: A Meta-Analysis

Pyoderma gangrenosum and Sweet syndrome: the prototypic neutrophilic dermatoses

Contact Info

Product

Resources

About